

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	Unassigned 10/530401
		Filing Date	April 8, 2005
		First Named Inventor	Manami TANAKA
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Date Submitted: April 7, 2005		Attorney Docket Number	081356-0240
(use as many sheets as necessary)			
Sheet	1	of	1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
/ML/		A1	JP 2000-139470		AGENCY OF IND SCIENCE AND TECHNOL	5/23/2000		
/ML/		A2	JP 2001-161384		NAT'L INST OF ADVANCED INDUSTRIAL SCIENCE & TECHNOLOGY	6/19/2001		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
/ML/	A3	International Search Report of PCT/JPO2/10599	
/ML/	A4	Manami TANAKA et al., "Characterization of Tissue- and Cell-Type-Specific Expression of a Novel Human Septin Family Gene, Bradeion", Biochemical and Biophysical Research Communications, Vol. 286, No. 3, (2001), pp. 547-553.	
/ML/	A5	Manami TANAKA et al., "Impaired expression of a human septin family gene Bradeion inhibits the growth and tumorigenesis of colorectal cancer <i>in vitro</i> and <i>in vivo</i> ", Cancer Gene Therapy (2002), 9, pp. 483-488.	

Examiner Signature	/Maria Leavitt/	Date Considered	08/14/2008
-----------------------	-----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.